NASDAQ:CBLI Cleveland BioLabs (CBLI) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free CBLI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.0007▼$0.000750-Day Range$2.20▼$4.3452-Week Range$1.62▼$10.97Volume5,001 shsAverage Volume271,922 shsMarket Capitalization$10,835.30P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Cleveland BioLabs alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Cleveland BioLabs Stock (NASDAQ:CBLI)Cytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" CBLI Stock News HeadlinesSeptember 2, 2023 | usatoday.comEagles' Tyrie Cleveland, Moro Ojomo carted off field after suffering neck injuriesJuly 28, 2023 | bizjournals.comCleveland Construction NewsApril 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…June 28, 2023 | health.usnews.comBest Hospitals in Cleveland, OHMay 22, 2023 | abcnews.go.comCleveland EMS worker who went missing for 6 days remains hospitalized after found safeMay 17, 2023 | health.usnews.comCleveland Clinic Rehabilitation HospitalApril 19, 2023 | travel.usnews.comGetting Around ClevelandMarch 31, 2023 | thestreet.comCleveland BioLabs Stock Gaps Down On Today's Open (CBLI)April 25, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 23, 2023 | bizjournals.comCleveland Manufacturing NewsMarch 16, 2023 | bizjournals.comCleveland Commercial Real Estate NewsMarch 12, 2023 | forbes.comCleveland, TNSeptember 9, 2022 | bizjournals.comCleveland NewsAugust 31, 2022 | thestreet.com5 Stocks Under $5 Making Big MovesNovember 15, 2021 | finance.yahoo.comStatera Biopharma Provides Third Quarter 2021 Financial and Corporate UpdateOctober 26, 2021 | finance.yahoo.comCleveland BioLabs Gets Orphan Status for Entolimod in EUSeptember 24, 2021 | reuters.comStatera Biopharma IncSeptember 8, 2021 | finance.yahoo.comWhat is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?September 7, 2021 | finance.yahoo.comStatera BioPharma: The Ticker Formerly Known as CBLISeptember 2, 2021 | seekingalpha.comCytocom to rename as Statera BioPharmaAugust 31, 2021 | finance.yahoo.comCytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."August 18, 2021 | seekingalpha.comCytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call TranscriptAugust 16, 2021 | finance.yahoo.comCytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via WebcastAugust 16, 2021 | finance.yahoo.comCytocom, Inc. Reports Second Quarter 2021 Financial ResultsAugust 12, 2021 | finance.yahoo.comCytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance AgreementAugust 11, 2021 | finance.yahoo.comCytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business ConferenceAugust 10, 2021 | finance.yahoo.comCytocom, Inc. to Report Second Quarter 2021 Financial ResultsSee More Headlines Receive CBLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cleveland BioLabs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2020Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CBLI CUSIPN/A CIK1318641 Webwww.cbiolabs.com Phone(888) 613-8802FaxN/AEmployees4Year Founded2003Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,400,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.84% Return on Assets-31.29% Debt Debt-to-Equity RatioN/A Current Ratio45.93 Quick Ratio45.93 Sales & Book Value Annual Sales$260,000.00 Price / Sales0.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book0.00Miscellaneous Outstanding Shares15,479,000Free FloatN/AMarket Cap$10,835.30 OptionableNot Optionable Beta0.70 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMichael Kevin HandleyPresident, Chief Executive Officer & DirectorTaunia S. MarkvickaChief Operating Officer & DirectorPeter J. AronstamChief Financial OfficerAndrei V. GudkovGlobal Head-Research & DevelopmentClifford A. SelskyChief Medical OfficerKey CompetitorsNovanNASDAQ:NOVNNVN LiquidationNASDAQ:NOVNQStatera BiopharmaNASDAQ:STABGenocea BiosciencesNASDAQ:GNCAHTG Molecular DiagnosticsNASDAQ:HTGMQView All Competitors CBLI Stock Analysis - Frequently Asked Questions How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its quarterly earnings results on Friday, May, 15th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.16 million for the quarter. What other stocks do shareholders of Cleveland BioLabs own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cleveland BioLabs investors own include iBio (IBIO), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Biocept (BIOC) and Co-Diagnostics (CODX). This page (NASDAQ:CBLI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
